Sign In
Buy APVO
$5.02
-0.0200 (-0.397%)
At Close: Jun 03, 2026
New Coronavirus Vaccine To Send Virus' Spike Protein To Activate Body's Immune Response
12:00pm, Tuesday, 26'th May 2020
Novavax is now beginning its clinical trials.
Aptevo Therapeutics Reports First Quarter 2020 Financial Results
01:00pm, Wednesday, 13'th May 2020
Advances Phase 1/1b Clinical Trial of APVO436 for the Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Cohort 6 Enrollment Ongoing Reports Preliminary Evidence of a Potenti
Week 6 results from Sermo’s COVID-19 Real Time Barometer with 6,150 physicians reveals COVID-19 treatment patterns among frontline physicians. In tota
Zogenix appoints Shawnte Mitchell as EVP, general counsel, secretary ZGNX;APVO
12:36pm, Monday, 20'th Apr 2020
Zogenix appoints Shawnte Mitchell as EVP, general counsel, secretary ZGNX APVO
Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements
01:00pm, Tuesday, 14'th Apr 2020
SEATTLE, WA / ACCESSWIRE / April 14, 2020 / Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispec
The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends Guidance
12:02pm, Friday, 27'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
None of the NYSE- or Nasdaq-listed biotech stocks hit 52 week highs Thursday.
Down In The...
Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update
01:00pm, Wednesday, 25'th Mar 2020
Advances Dose-Escalation Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome Reports Preliminary Evidence of Clinical Activity of APVO436; Dosin
Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial
01:00pm, Monday, 16'th Mar 2020
At present, dosing in cohorts 1 through 5 has been completed with dosing in cohort 6 scheduled to begin shortly. No evidence of dose-limiting toxicities was observed in the latest dose cohort (cohort
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dum
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
12:03pm, Wednesday, 11'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * A
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Enz
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
01:05pm, Thursday, 05'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences In
Aptevo Therapeutics Sells IXINITY Hemophilia B Therapy for Estimated Proceeds in Excess of $100 Million
02:05pm, Friday, 28'th Feb 2020
Transforms Aptevo into a ‘Pure Play' Biotechnology Company Focused on the Development of Proprietary ADAPTIR™ Bispecific Antibody Therapeutics Strengthens Aptevo's Financial Position; Eliminates M
